Jason Duncan - 24 Oct 2022 Form 4 Insider Report for ALBIREO PHARMA, INC.

Signature
/s/ Jason Duncan
Issuer symbol
N/A
Transactions as of
24 Oct 2022
Net transactions value
-$12,756
Form type
4
Filing time
25 Oct 2022, 16:00:40 UTC
Previous filing
25 Jul 2022
Next filing
27 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale $2,036 -104 -0.67% $19.58 15,483 24 Oct 2022 Direct F1, F2
transaction ALBO Common Stock Sale $1,876 -96 -0.62% $19.54 15,387 24 Oct 2022 Direct F1, F3
transaction ALBO Common Stock Sale $8,845 -456 -3% $19.40 14,931 24 Oct 2022 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2 Represents 1,276 shares of common stock and 14,207 restricted stock units.
F3 Represents 1,180 shares of common stock and 14,207 restricted stock units.
F4 Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.2697 to $19.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 Represents 724 shares of common stock and 14,207 restricted stock units.